<b>Background and Clinical Significance</b>: Over the last two decades, glucagon-like peptide-1 (GLP-1) receptor agonists have dramatically improved the management of type 2 diabetes mellitus and obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.